Chau Charlene Y C, Chow Loraine L W, Sridhar Siddharth, Shih Kendrick C
Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR.
Ophthalmol Ther. 2021 Jun;10(2):201-209. doi: 10.1007/s40123-021-00338-1. Epub 2021 Mar 6.
The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies.
2019年冠状病毒病（COVID-19）大流行对全球造成的影响可能会因安全有效的疫苗的推出和在全球范围内的传播而很快得到缓解。COVID-19疫苗如此迅速的研发和审批时间表是科学界前所未有的非凡协同成就。随着即将在全球范围内推出作用机制各异的疫苗，各专科医生将需要识别易受影响的患者群体，以便给予特殊考虑或建议。在这篇评论中，我们分析了炎症性眼病患者接种COVID-19疫苗的重要注意事项。仔细研究免疫原性和不良反应，尤其是抗体依赖增强作用，将更有助于为这些接种疫苗的患者提供咨询。开展更多关于药物警戒的研究将有助于制定针对性的指南和个性化管理策略。
